The Metabolic Characteristics in Sublobar Areas of PRE Based on FDG-PET Study

  • End date
    Dec 26, 2024
  • participants needed
  • sponsor
    Second Affiliated Hospital, School of Medicine, Zhejiang University
Updated on 26 January 2021


Epilepsy is a chronic brain disease that is caused by various factors and characterized by recurrent, episodic and temporary central nervous system dysfunction. In the past few decades, despite the continuous development of antiepileptic drugs, there are still 20%-30% patients with epilepsy progressing to pharmacoresistant epilepsy (PRE), which leads to a significant increase in the morbidity and mortality of epilepsy. For those fraction of PRE, surgical treatment may be the only possible way to cure epilepsy. Accurate presurgical evaluation play an important role in making surgery decision and defining surgical extent and achieve better surgical outcome. Imaging, especially interictal fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) is widely used in preoperative evaluation, which is of great significance in the detection of epileptogenic foci. Previous studies on FDG-PET have found that FDG-PET has a wide range of hypometabolism inpatients of PRE varying from different epileptic origins. Therefore, exploring the characteristics of glucose metabolism originating in different brain areas of resistant epilepsy can help to better interpret the results of FDG-PET and guide the preoperative localization of such patiens and better understand the potential mechanism of seizure propagation in PRE.

Condition Interictal FDG-PET Hypometabolism Patterns, Interictal FDG-PET Hypometabolism Patterns, Interictal FDG-PET Hypometabolism Patterns
Treatment Non Interventional
Clinical Study IdentifierNCT04642573
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

(a) Pharmacoresistant Epilepsy may be defined by
International League Against Epilepsy (ILAEas failure of adequate trials of
two tolerated and appropriately chosen and used AED schedules (whether as
monotherapies or in combination) to achieve sustained seizure freedom (judged
by two epileptologists); (b) conventional MRI negative or nonspecific
abnormalities; and (c) detailed information of long-term video-EEG, FDG-PET
high resolution MRI (HR-MRI) and neuropsychological assessment were acquired
(d) focal epilepsy defined by combining clinical, electrophysical and

Exclusion Criteria

(a) generalized or multifocal epilepsy or the patient's
electroclinical features were inconsistent with pharmacoresistant epilepsy
(b) idiopathic focal epilepsy; and (c) unsatisfactory imaging quality
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note